Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease

GL Pharm Tech

Status and phase: Unknown; Phase 2

Conditions: Dry Eye Syndromes

Treatments: Drug: 5% GLH8NDE; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04679883

GLH8NDE-201

Details and patient eligibility

About

This study is a randomized, double-blind, placebo-controlled phase 2 clinical trial to evaluate the efficacy and safety of GLH8NDE in patients with Dry Eye Disease.

Enrollment: 99 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject who is the age of older than 19 years at the screeing visit

• Subject who has symptom at least one or more as below for six months(Irritation, foreign body sensation, burning, mucus discharge, blurring, itching, photophobia, tired or heavy feeling and pain)

• Subject with dry eye syndrome who meet all of the following criteria among the left and/or right eyes at the time of screening and baseline visit.

  1. Over six grade as fluorescein corneal staining by National Eye Institute scale
  2. Schirmer I test ≤ 10 mm/5 min.
  3. TFBUT ≤ 6 seconds

• At the screening and baseline visit, the intraocular pressure(IOP) of both eyes is more than 5 mmHg and below 22 mmHg

• At the screening and baseline visit, biocular best corrected visual acuity(BCVA) are over 0.2(=+0.7 logMAR or Snellen 20/100)

• At the baseline visit, over 80% administration compliance during run-in period as placebo in single blind

• Subject who signed and dated the informed consent form after understanding fully to hear a detailed explanation in the clinical trial

Exclusion criteria

• Ophthalmic diseases that may confuse the interpretation of clinical trial results, such as clinically significant corneal surface disease, abnormal corneal sensitivity, and abnormal tearing

• Subject with wounds caused by refractive surgery such as LASIK surgery (However, if it does not affect the clinical trial compliance and result evaluation according to the investigator's judgment, participation is possible.)

• Subject with the following concomitant diseses at screening visit.

  1. Eyelid disease (blepharopathy, blepharolysis, valgus, varus valgus, etc.), conjunctival relaxation, cataracts, and eye diseases requiring treatment
  2. Sjogren's syndrome and secondary Sjogren's syndrome (rheumatoid arthritis, systemic lupus erythematosus, etc.)
  3. Diabetes not controlled despite appropriate treatment (hemoglobin A1c (HbA1c)> 9%)
  4. Subject with the following systemic diseases that are not controlled High blood pressure that is not controlled despite administration of antihypertensive drugs (systolic blood pressure (SBP)/diastolic blood pressure (DBP)>160/100 mmHg) Clinically significant cardiopulmonary disease despite appropriate treatment
  5. Acute active hepatitis A, active hepatitis B or C

• Subject with the following medical history (including surgical history) at screening visit

  1. Organ transplant or bone marrow transplant
  2. History of known immunodeficiency disease or human immunodeficiency virus (HIV) infection
  3. Ophthalmic surgery within 1 year before screening (including LASIK/LASEK surgery)
  4. Subject who has undergone punctal occlusion and have not passed 12 weeks from the time point below.

After punctal cauterization using electrocautery. After inserting a permanent, semi-permanent punctal plug. If a temporary punctal plug is inserted, remove the punctal plug.

• Subject who has administered the following drugs before the clinical trial or who need to be administered during the clinical trial.

  1. Cyclosporine eye drops within 6 weeks before screening
  2. Ophthalmic solutions or antibiotics due to blepharitis, meibomian gland disease, herpes zoster, and eye infection within 6 weeks before screening
  3. Drugs that cause dry eye within 6 weeks before screening (anticholinergics, isotretinoin, etc.)
  4. Oral aspirin or drugs containing aspirin within 6 weeks before screening
  5. Contains corticosteroids, mast cell stabilizers, antihistamines, anti-inflammatory drugs (NSAIDs, etc.), gamma linolenic acid, or omega-3 fatty acids within 6 weeks before screening
  6. Other ophthalmic solutions within 3 days before screening

• Subject who wears contact lenses within 1 week before screening or who needs to wear them during the clinical trial

• Subject with alcoholism or drug abuse history within 1 year before screening

• Pregnant women, lactating women, and those who disagree with appropriate contraception during the clinical trial (visit 1 to visit 6)

• Subject with hypersensitivity to investigator's drugs or their excipients

• Subject who participated in other clinical trials within 4 weeks before screening and received/received investigator's drug or clinical trial medical devices

• Subject judged by other investigators to be inappropriate to participate in this clinical trial

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

99 participants in 3 patient groups, including a placebo group

GLH8NDE 5% and GLH8NDE Placebo

Experimental group

Description:

Three times each 1 drop a day, total 6 times 1 drop of GLH8NDE 5% and GLH8NDE Placebo

Treatment:

Drug: 5% GLH8NDE

Drug: Placebo

GLH8NDE 5%

Experimental group

Description:

Total 6 times 1 drop of GLH8NDE 5%

Treatment:

Drug: 5% GLH8NDE

GLH8NDE Placebo

Placebo Comparator group

Description:

Total 6 times 1 drop of GLH8NDE Placebo

Treatment:

Drug: Placebo